- Home
- TII vs PROK Comparison
TII vs PROK Comparison
Compare TII & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | PROK |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.0M | 269.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TII | PROK |
|---|---|---|
| Price | $2.77 | $1.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.38 | ★ $7.40 |
| AVG Volume (30 Days) | 252.1K | ★ 835.6K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.09 | $0.54 |
| 52 Week High | $5.65 | $7.13 |
Technical Indicators
Market Signals| Indicator | TII | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 48.59 |
| Support Level | $2.48 | $1.71 |
| Resistance Level | $3.35 | $2.58 |
| Average True Range (ATR) | 0.23 | 0.14 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 27.71 | 82.07 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. It is engaged in the acquisition, exploration, and development of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States. The Company operates one reportable segment, mineral production and exploration in the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.